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background:  Multiple studies have evaluated copeptin, a surrogate for arginine vasopressin, in the diagnosis of acute myocardial infarction 
(AMI) with mixed results. We performed a collaborative meta-analysis for diagnosis of AMI and assessment of prognosis in patients presenting to the 
emergency department with chest pain.
methods: MEDLINE/PubMed, Cochrane CENTRAL, and EMBASE were searched for studies assessing copeptin in patients presenting to the 
emergency department with chest pain. Study authors were contacted and many provided previously unpublished data. Following data extraction, 
random-effects methods were used to compare the data for copeptin, troponin, and their combination.
results: From the 14 included studies, there were a total of 9,244 patients. Mean age was 62 years; 64% were male; and 18.4% were ultimately 
diagnosed with AMI. Patients with AMI had a higher presentation copeptin level than those without AMI (22.9 vs. 7.9 pmol/L, p <0.001). While 
troponin had better diagnostic accuracy than copeptin for AMI, the combination of copeptin and the admission troponin significantly improved 
sensitivity and negative predictive value (NPV) compared with troponin alone, regardless of whether using conventional or high-sensitivity troponin. 
However, the addition of copeptin to the admission troponin did not significantly improve overall diagnostic accuracy assessed by summary ROC 
curves when compared with troponin alone. Elevation in copeptin carried a similar risk of all-cause mortality to an elevation in troponin (odds ratio 
5.84 vs. 6.74, respectively, p=0.67).
Conclusions: Copeptin not only identifies patients at risk for all-cause mortality, but its addition to troponin improved sensitivity and negative 
likelihood ratio for diagnosis of AMI compared with troponin alone. Thus, assessment of copeptin may improve early identification of AMI and help 
identify patients who may be safely discharged early from the emergency department.
